▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Brian Feroldi

TMFTypeoh

Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here.

Recent Articles by Brian Feroldi

stethoscope on top of money

Jul 15, 2016 by Brian Feroldi

Why Ionis Pharmaceuticals Inc. Is Surging Today

Sometimes no news is good news.

GettyImages-107429830

Jul 14, 2016 by Brian Feroldi, Keith Speights, and Cory Renauer

An Aging Population Makes These 3 Stocks Screaming Buys

The American population is getting older, which is a big reason our contributors are bullish on these three stocks.

Lobby-view

Jul 13, 2016 by Brian Feroldi

Why Imprivata Inc. Is Soaring Today

News that the company is being acquired by a private equity firm sent shares screaming higher.

GettyImages-97134518

Jul 13, 2016 by Brian Feroldi, Tyler Crowe, and Timothy Green

3 Stocks We're Watching in the 3rd Quarter

Here's why our team of contributors will be keeping a close watch on these three companies this quarter.

GettyImages-502850486

Jul 12, 2016 by Brian Feroldi

Why Shares of NetSuite Inc. Are Up Big Today

Shares popped in response to rumors that the company might receive a takeover offer.

GettyImages-507159879

Jul 12, 2016 by Brian Feroldi

Here's Why SAGE Therapeutics Inc. Is Surging Today

Encouraging data from a phase 2 study puts the markets in a good mood.

amgen4

Jul 12, 2016 by Brian Feroldi

Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharmaceuticals Inc and Sanofi SA (ADR)

Amgen has won FDA approval for a new device that allows for monthly dosing of its cholesterol-busting drug Repatha. Is it a game-changing innovation in its fight against Regeneron Pharmaceuticals and Sanofi?

Man picking money out of tree dividends income

Jul 8, 2016 by Brian Feroldi, Sean Williams, and Tyler Crowe

3 Warren Buffett Stocks to Supercharge Your Portfolio

Warren Buffett is a big believer in these three stocks. Perhaps you should be, too.

Man on risk arrow pointing down

Jul 8, 2016 by Brian Feroldi

3 Shocking Biotech Flops of 2016 So Far

Shareholders of these clinical-stage drugmakers have had a rotten first half. Are there any hopes for rebounds in the second half or beyond?

Jul 6, 2016 by Brian Feroldi

Can Vertex Pharmaceuticals Incorporated Bounce Back From Its 28.9% Drop?

It's been a tough start to the year for investors in this biopharma. What needs to happen for this company's stock to get back on track?

PHOTO CREDIT TBIT ON PIXABAY

Jul 6, 2016 by Brian Feroldi

The Probable Reason Behind Nektar Therapeutics Inc.'s 15.5% Year-to-Date Drop

Despite releasing a series of positive announcements, shares still slumped. Here's why.

Image by nvodicka via pixabay

Jul 5, 2016 by Brian Feroldi

After a 31% Decline, Can Shares of Ophthotech Inc. Bounce Back Later This Year?

It's been a rough year for the clinical-stage biotech. Here's a look back at the key events that have contributed to the stock's decline.

GettyImages-478054915

Jul 4, 2016 by Brian Feroldi

3 Top Healthcare Stocks to Buy Now

The market's recent jitters are creating great opportunities to buy quality companies at favorable prices.

GettyImages-450910493

Jul 4, 2016 by Brian Feroldi

Sarepta Therapeutics Inc's Stock Has Plunged 47% in 2016. Here's Why.

It's been a wild year for the clinical-stage biotech.

dividends growth coins stacked higher

Jul 2, 2016 by Brian Feroldi

3 Healthcare Stocks That Could Raise their Dividends

Looking for a dividend-paying stock that can grow its payout over time? Here are three healthcare stocks for you to consider.

REGNcourtyard_l

Jul 1, 2016 by Brian Feroldi

Here's Why Regeneron Pharmaceuticals Inc Is Down 35% This Year

Positive clinical news is being overshadowed by an unfavorable court ruling and slowing growth of its core business.

Screen Shot 2016-06-22 at 10.34.09 AM

Jun 30, 2016 by Brian Feroldi

Why Organovo Holdings Inc. Is Up 27% This Year

Shares are off to a great start to the year. Here's a recap of the key developments that have caused the stock to jump this much.

money raining down on man with unbrella

Jun 29, 2016 by Brian Feroldi

Shares of Tesaro, Inc. Have More Than Doubled Today. Here's Why

The company reported great-looking data from a pivotal phase 3 trial, causing shares to skyrocket.

GettyImages-108359303

Jun 29, 2016 by Brian Feroldi, Daniel Miller, and Matt DiLallo

3 Retirement Stocks to Buy in July

Here's a list of three companies that are great choices for investors in their golden years.

Money falling from sky buyout takeover riches

Jun 28, 2016 by Brian Feroldi

Why Xencor Inc's Shares Are Skyrocketing Today

The signing of a lucrative partnership agreement with a pharma giant sends shares soaring.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services